News

• March 14, 2024

  Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development >

  Positive top-line data from Phase 2 dose exploration study of nomlabofusp, which was generally well-tolerated, with dose-dependent increases in tissue frataxin levels observed Initiated discussions with the Food and Drug Administration (FDA) on the potential use of tissue frataxin levels as a novel

• March 11, 2024

  Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’s Ataxia >

  Study will inform on long-term safety profile and tissue frataxin levels OLE initiated with 25 mg daily subcutaneous injections of nomlabofusp Frataxin data and safety data from the OLE study are intended to help support a potential Biologics License Application (“BLA”) submission for accelerated

• March 6, 2024

  Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference >

  BALA CYNWYD, Pa. , March 06, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics , Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company’s management team will present and participate

• February 16, 2024

  Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares >

  BALA CYNWYD, Pa. , Feb. 16, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the closing of its previously announced underwritten public offering of

• February 14, 2024

  Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock >

  BALA CYNWYD, Pa. , Feb. 14, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the pricing of its previously announced underwritten public offering of

• February 13, 2024

  Larimar Therapeutics Announces Proposed Underwritten Public Offering >

  BALA CYNWYD, Pa. , Feb. 13, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has commenced an underwritten public offering of shares of its

• February 12, 2024

  Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich’s Ataxia >

  Nomlabofusp was generally well tolerated following repeated subcutaneous injections in patients in the 25 and 50 mg cohorts with no serious adverse events Dose dependent increases in frataxin levels were observed in skin and buccal cells Open Label Extension (OLE) study initiated in January 2024 to

• November 14, 2023

  Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results >

  Completed full enrollment and dosing of the 50 mg cohort in Phase 2 Friedreich's ataxia (FA) dose exploration trial; based on blinded observations during the dosing period, there were no serious adverse events in either the CTI-1601 (nomlabofusp) or placebo groups.

• November 1, 2023

  Larimar Therapeutics to Present at the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference >

  BALA CYNWYD, Pa. , Nov. 01, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc.   (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company’s management team will participate in a

• October 3, 2023

  Larimar Therapeutics Appoints Dr. Jeffrey W. Sherman to its Board of Directors >

  BALA CYNWYD, Pa. , Oct. 03, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the appointment of Jeffrey W. Sherman , M.D., F.A.C.P.

• August 31, 2023

  Larimar Therapeutics to Present at the Citi 18th Annual BioPharma Conference >

  BALA CYNWYD, Pa. , Aug. 31, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc.   (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in a panel discussion and 1x1

• August 10, 2023

  Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results >

  Initiation cleared for 50 mg cohort in Phase 2 Friedreich's ataxia (FA) dose exploration trial following FDA review of unblinded 25 mg cohort Phase 2 data Initiation cleared for open-label extension (OLE) trial following FDA review of unblinded 25 mg cohort Phase 2 data Top-line safety,

• July 25, 2023

  Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601’s Phase 2 Friedreich's Ataxia Trial and to Initiate Open Label Extension Trial >

  Top-line safety, pharmacokinetic, and pharmacodynamic (frataxin level) data from Phase 2 trial’s 50 mg cohort expected in 1H 2024 Initiation of open label extension trial with 25 mg daily dosing expected in Q1 2024; interim data expected in Q4 2024 Company management hosting a webcast and

• July 17, 2023

  Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer >

  BALA CYNWYD, Pa. , July 17, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the appointment of Russell “Rusty” Clayton, DO, as Chief Medical Officer

• June 21, 2023

  Larimar Therapeutics Set to Join Russell 3000® Index >

  BALA CYNWYD, Pa. , June 21, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it is set to join the broad-market Russell 3000 Index at the conclusion

• May 15, 2023

  Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trial’s 25 mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreich’s Ataxia and First Quarter 2023 Financial Results >

  Safety data indicate that repeated subcutaneous injections of 25 mg CTI-1601 were generally well tolerated when administered daily for 14 days and then every-other-day thereafter until day 28 Daily subcutaneous injections of 25 mg CTI-1601 for 14 days led to increases in frataxin levels from

• March 28, 2023

  Larimar Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Days >

  BALA CYNWYD, Pa. , March 28, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in a virtual fireside chat and 1x1

• March 14, 2023

  Larimar Therapeutics Reports Fourth Quarter and Full Year 2022 Operating and Financial Results >

  First cohort of Larimar’s Phase 2 dose exploration trial of CTI-1601 in participants with Friedreich’s ataxia (FA) is fully enrolled and proceeding as planned Larimar expects to provide an update on the next steps of the Phase 2 trial in Q2 2023, after the FDA and independent data monitoring

• February 7, 2023

  Larimar Therapeutics Appoints Dr. Gopi Shankar as Chief Development Officer >

  Biologics expert and long-time veteran of Johnson & Johnson will be responsible for the strategic development of Larimar’s clinical and R&D programs BALA CYNWYD, Pa. , Feb. 07, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company

---

View all News >